Skip to content

New Local Treatment of Radiation-induced Proctitis

New Option for the Treatment of Radiation-induced Proctitis Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05489107
Acronym
NOTRIP
Enrollment
50
Registered
2022-08-05
Start date
2022-07-01
Completion date
2023-07-31
Last updated
2022-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radiation Proctitis

Keywords

radiation, proctitis, hyaluronic acid, chondroitin sulfate, poloxamer 407, local treatment, rectoscopy

Brief summary

A prospective single-center observational study to evaluate the effectiveness of a local treatment with a mixture of hyaluronic acid, chondroitin sulfate and poloxamer 407 in patients with radiation-induced proctitis.

Interventions

OTHERZiverel

Within a first flexible rectoscopy (Day 1) the product will be applied transanally. Then the patients will apply it as enemas twice daily for 7 days. On day 8 (after treatment completion), and on day 31 (after 23 days of no treatment) follow-up flexible rectoscopies will be performed.

Sponsors

Barmherzige Brüder Vienna
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* proven symptomatic acute or chronic radiation-induced proctitis; * current or prior radiation therapy in the pelvic area; * patients with complications connected to the radiation therapy.

Exclusion criteria

* lack of informed consent; * non-adherence to study protocol; * pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Number of Petechiae in the most affected areas of the rectal mucosa.1 monthAssessment of the effects of the mixture on the number of petechiae in the rectum. Within the first flexible rectoscopy (Day 1) the most affected areas of the rectal mucosa (on the anterior and posterior wall) will be determined. A 27 mm CAPTIVATOR hexagonal polypectomy snare (Boston Scientific) will be introduced through the endoscope, and will be fully opened. The fully open polypectomy snare (9,2 cm2) will be applied over the most affected areas on the anterior and posterior rectal wall, and the number of the petechiae within these areas will be documented. The flexible rectoscopy will be repeated on day 8 after patients have already received enemas with the examined substance twice daily for one week, and the number of the petechiae will be documented as above mentioned. After a period of 23 days with no treatment, a follow-up flexible rectoscopy will be performed on day 31, and the petechiae of the rectal mucosa will be once more assessed.

Secondary

MeasureTime frameDescription
Assessment of patients' quality of life using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Proctitis Module with 20 Questions (EORTC QLQ-PRT20)6 monthsThe effects of the mixture on subjects' quality of life will be assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Proctitis Module with 20 Questions Score (EORTC QLQ-PRT20). The questionnaire consists of 18 quantitative, 2 qualitative (one of them being optional), and 1 semi-quantitative questions . Using the quantitative questions, a score can be defined. Its minimum value is 18 (meaning patients have no symptoms), and its maximum value is 72 (meaning greatest extent of lifestyle limitations because of radiation proctitis). The semi-quantitative question provides information about the highest number of defecations per 24 hours and is not included in the score. The qualitative questions determine the use of medicines, and patients' will to receive any assistance concerning their symptoms. The score will be documented on day 1, 8, 31 and 6 months after treatment completion.

Countries

Austria

Contacts

Primary ContactIliyan Iliev, MD
iliyaniliev18s@gmail.com0043 1 21121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026